Suchergebnisse - "Brown, Jennifer R"

PubPharm (42)

1

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

enthalten in: Molecular cancer therapeutics | 2024

von Arribas, A. | Napoli, S. | Cascione, L. | +21

UpdateOf: bioRxiv. 2023 Jan 02;:. - PMID 36711490

2

Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition

enthalten in: Leukemia & lymphoma | 2023

von Leung, B. | Fay, C. | Said, J. | +7

3

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

enthalten in: Blood | 2023

von Seymour, J. | Byrd, J. | Ghia, P. | +15

CommentIn: Blood. 2023 Aug 24;142(8):679-680. - PMID 37616021

4

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Mato, A. | Woyach, J. | Brown, J. | +32

5

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

enthalten in: Blood advances | 2023

von Naeem, A. | Utro, F. | Wang, Q. | +22

CommentIn: Blood Adv. 2023 May 9;7(9):1926-1928. - PMID 36355806

6

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma : Interim Analysis of a Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Hillmen, P. | Eichhorst, B. | Brown, J. | +25

7

PI3K inhibitors in chronic lymphocytic leukemia : where do we go from here?

enthalten in: Haematologica | 2023

von Skånland, S. | Brown, J.

8

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

enthalten in: Haematologica | 2022

von Arribas, A. | Napoli, S. | Cascione, L. | +22

9

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy : pooled analysis of 762 patients

enthalten in: Haematologica | 2022

von Brown, J. | Byrd, J. | Ghia, P. | +12

CommentIn: Haematologica. 2022 Jun 01;107(6):1489-1490. - PMID 34788988

10

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

enthalten in: Haematologica | 2022

von Allan, J. | Pinilla-Ibarz, J. | Gladstone, D. | +16

1
2
3
4
5
Nächster »
[5]